Abstract
Exposure to environmental toxicants such as Arsenic (As) can result in As-induced alterations in immune regulators. Consequently, people who are more prone to viral infections like influenza A or B, H1N1, SARS CoV (Severe Acute Respiratory Syndrome Coronavirus), and SARS CoV2 may develop a susceptibility to immune responses in their lungs because our previous reports delineated the ability of QIAPI 1®, a melanin precursor, to dissociate water molecules with simultaneous therapeutic efficacy against central nervous system (CNS) diseases, retinopathy, and As-induced renal toxicity. Considering the commonalities of lung pathology of SARS CoV and As-induced toxicity, the aim of this study is to decipher the efficacy of QIAPI 1® against pentavalent As-induced lung toxicity by examining the pulmonary pathology. Hematoxylin & Eosin (H&E) staining was used for ascertaining the lung pathology in Wistar rat models. Animals were divided into 3 groups: control group, group treated with pentavalent As, and a group treated with pentavalent As and QIAPI 1®. There were no significant changes in lung histopathology in the control group as indicated by intact morphology. The As-treated group revealed damage to the histoarchitecture with pulmonary edema, interstitial fibrosis, diffuse alveolar damage, Bronchiolitis obliterans organizing pneumonia (BOOP)-lesions, formation of hyaline membrane, multinucleated giant pneumocytes, atypical pneumocytes, inflammatory cell infiltration, and interstitial edema. The group treated with As and QIAPI 1® significantly associated with mitigated histological signs of lung inflammation induced by Arsenic. Therefore, QIAPI 1® can be recommended as antagonistic to Asinduced lung toxicity. In conclusion, this model could be preferred as a hypothetical model to examine the efficacy of QIAPI 1® in SARS CoV2-induced pulmonary damage. Future studies are warranted to delineate the efficacy of QIAPI 1® against SARS CoV and SARS CoV2 lung pathology.
Keywords: COVID-19, SARS-CoV2, QIAPI1®, alveoli, arsenic, lung toxicity, fibrosis.
Graphical Abstract
[http://dx.doi.org/10.1053/j.semdp.2017.06.005]
[http://dx.doi.org/10.1378/chest.125.4.1343] [PMID: 15078744]
[http://dx.doi.org/10.1097/QCO.0b013e328328cf65] [PMID: 19276881]
[http://dx.doi.org/10.1016/0034-5687(78)90104-4] [PMID: 644146]
[http://dx.doi.org/10.1183/09031936.00037014]
[http://dx.doi.org/10.1038/s41598-017-06791-y] [PMID: 28740106]
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.04.008] [PMID: 21554949]
[http://dx.doi.org/10.1016/j.mrfmmm.2003.07.009] [PMID: 14643412]
[http://dx.doi.org/10.1186/1476-4598-12-20] [PMID: 23510327]
[http://dx.doi.org/10.1016/j.envint.2017.04.008] [PMID: 28625818]
[http://dx.doi.org/10.1093/aje/kwt059] [PMID: 23764934]
[http://dx.doi.org/10.1016/j.biochi.2014.08.017] [PMID: 25194983]
[http://dx.doi.org/10.1111/j.1365-2133.2003.05704.x] [PMID: 14674888]
[http://dx.doi.org/10.1016/j.envres.2016.04.030] [PMID: 27136670]
[http://dx.doi.org/10.1289/ehp.1002265] [PMID: 21147604]
[http://dx.doi.org/10.1016/j.neuro.2011.07.004] [PMID: 21839772]
[http://dx.doi.org/10.1016/j.taap.2014.06.006] [PMID: 24952339]
[http://dx.doi.org/10.1007/s11356-016-7886-4] [PMID: 27761864]
[http://dx.doi.org/10.1007/s12011-017-1111-2] [PMID: 28803342]
[http://dx.doi.org/10.1080/14786419.2014.921786] [PMID: 24896611]
[http://dx.doi.org/10.1016/j.bbrc.2014.12.010] [PMID: 25499816]
[http://dx.doi.org/10.1371/journal.pone.0025886] [PMID: 22003413]
[http://dx.doi.org/10.1038/jes.2009.24] [PMID: 19401722]
[http://dx.doi.org/10.1016/j.juro.2009.02.149] [PMID: 19450849]
[http://dx.doi.org/10.3961/jpmph.14.035] [PMID: 25284195]
[http://dx.doi.org/10.1289/ehp.99107593] [PMID: 10379007]
[http://dx.doi.org/10.1289/ehp.9297259] [PMID: 1396465]
[http://dx.doi.org/10.1081/ESE-120016885] [PMID: 12635823]
[http://dx.doi.org/10.1038/sj.jes.7500510] [PMID: 16835595]
[http://dx.doi.org/10.1016/j.toxlet.2009.01.001] [PMID: 19167470]
[http://dx.doi.org/10.1289/ehp.0900911] [PMID: 19750111]
[http://dx.doi.org/10.1093/toxsci/kfm200] [PMID: 17682005]
[http://dx.doi.org/10.1289/ehp.10861] [PMID: 18414638]
[http://dx.doi.org/10.1007/s10875-009-9280-1] [PMID: 19247822]
[http://dx.doi.org/10.4049/jimmunol.177.5.3019] [PMID: 16920938]
[http://dx.doi.org/10.1093/toxsci/kfm072] [PMID: 17400579]
[http://dx.doi.org/10.1289/ehp.0800199] [PMID: 19654921]
[http://dx.doi.org/10.1006/faat.1996.0004] [PMID: 8838638]
[http://dx.doi.org/10.1186/1465-9921-9-53] [PMID: 18627612]
[http://dx.doi.org/10.1093/toxsci/56.1.114] [PMID: 10869459]
[http://dx.doi.org/10.1371/journal.pone.0138182] [PMID: 26383851]
[http://dx.doi.org/10.1186/s12940-015-0069-9] [PMID: 26497043]
[http://dx.doi.org/10.1097/01.ede.0000181637.10978.e6] [PMID: 16222165]
[http://dx.doi.org/10.1093/aje/kwq383] [PMID: 21190988]
[http://dx.doi.org/10.1289/ehp.1306748] [PMID: 23968752]
[http://dx.doi.org/10.1093/toxsci/kfu113] [PMID: 24924402]
[http://dx.doi.org/10.1289/EHP318] [PMID: 28657894]
[http://dx.doi.org/10.1093/toxsci/kfr184] [PMID: 21750349]
[http://dx.doi.org/10.1093/jnci/djp414] [PMID: 19933942]
[http://dx.doi.org/10.1562/2004-08-03-RA-259.1] [PMID: 15504086]
[http://dx.doi.org/10.2174/1871527315666160202122943]
[http://dx.doi.org/10.4236/ijcm.2011.23058]
[http://dx.doi.org/10.4236/nm.2011.23029]
[http://dx.doi.org/10.2174/1871524919666190702164206]
[http://dx.doi.org/10.4172/2153-2435.s15-005]
[http://dx.doi.org/10.1136/jcp.2003.013276] [PMID: 14990596]
[http://dx.doi.org/10.1172/JCI200316867] [PMID: 12618521]
[http://dx.doi.org/10.2353/ajpath.2007.061088] [PMID: 17392154]
[http://dx.doi.org/10.1177/030098588602300308] [PMID: 3014706]
[http://dx.doi.org/10.1177/030098587501200305] [PMID: 1198873]
[http://dx.doi.org/10.1007/BF01314779] [PMID: 907478]
[http://dx.doi.org/10.1016/j.virol.2007.07.030] [PMID: 17804032]
[http://dx.doi.org/10.1016/j.jtho.2020.02.010] [PMID: 32114094]
[PMID: 24049627]
[http://dx.doi.org/10.1007/s12035-016-0288-2] [PMID: 27966075]
[http://dx.doi.org/10.1007/s12011-012-9374-0] [PMID: 22426748]
[PMID: 17519110]